S&P 500   2,488.65 (-1.51%)
DOW   21,052.53 (-1.69%)
QQQ   183.37 (-1.42%)
AAPL   241.41 (-1.44%)
FB   154.18 (-2.53%)
MSFT   153.90 (-0.88%)
GOOGL   1,092.70 (-2.18%)
AMZN   1,906.59 (-0.64%)
CGC   13.25 (-3.99%)
NVDA   243.91 (-4.52%)
BABA   187.11 (-0.95%)
MU   41.22 (+0.32%)
GE   6.73 (-2.46%)
TSLA   480.01 (+5.62%)
AMD   42.59 (-4.27%)
T   27.46 (-4.52%)
ACB   0.81 (-2.41%)
F   4.24 (-2.75%)
NFLX   361.76 (-2.25%)
BAC   20.03 (-2.63%)
GILD   78.21 (+1.60%)
DIS   93.88 (-3.19%)
PRI   80.69 (-2.50%)
S&P 500   2,488.65 (-1.51%)
DOW   21,052.53 (-1.69%)
QQQ   183.37 (-1.42%)
AAPL   241.41 (-1.44%)
FB   154.18 (-2.53%)
MSFT   153.90 (-0.88%)
GOOGL   1,092.70 (-2.18%)
AMZN   1,906.59 (-0.64%)
CGC   13.25 (-3.99%)
NVDA   243.91 (-4.52%)
BABA   187.11 (-0.95%)
MU   41.22 (+0.32%)
GE   6.73 (-2.46%)
TSLA   480.01 (+5.62%)
AMD   42.59 (-4.27%)
T   27.46 (-4.52%)
ACB   0.81 (-2.41%)
F   4.24 (-2.75%)
NFLX   361.76 (-2.25%)
BAC   20.03 (-2.63%)
GILD   78.21 (+1.60%)
DIS   93.88 (-3.19%)
PRI   80.69 (-2.50%)
S&P 500   2,488.65 (-1.51%)
DOW   21,052.53 (-1.69%)
QQQ   183.37 (-1.42%)
AAPL   241.41 (-1.44%)
FB   154.18 (-2.53%)
MSFT   153.90 (-0.88%)
GOOGL   1,092.70 (-2.18%)
AMZN   1,906.59 (-0.64%)
CGC   13.25 (-3.99%)
NVDA   243.91 (-4.52%)
BABA   187.11 (-0.95%)
MU   41.22 (+0.32%)
GE   6.73 (-2.46%)
TSLA   480.01 (+5.62%)
AMD   42.59 (-4.27%)
T   27.46 (-4.52%)
ACB   0.81 (-2.41%)
F   4.24 (-2.75%)
NFLX   361.76 (-2.25%)
BAC   20.03 (-2.63%)
GILD   78.21 (+1.60%)
DIS   93.88 (-3.19%)
PRI   80.69 (-2.50%)
S&P 500   2,488.65 (-1.51%)
DOW   21,052.53 (-1.69%)
QQQ   183.37 (-1.42%)
AAPL   241.41 (-1.44%)
FB   154.18 (-2.53%)
MSFT   153.90 (-0.88%)
GOOGL   1,092.70 (-2.18%)
AMZN   1,906.59 (-0.64%)
CGC   13.25 (-3.99%)
NVDA   243.91 (-4.52%)
BABA   187.11 (-0.95%)
MU   41.22 (+0.32%)
GE   6.73 (-2.46%)
TSLA   480.01 (+5.62%)
AMD   42.59 (-4.27%)
T   27.46 (-4.52%)
ACB   0.81 (-2.41%)
F   4.24 (-2.75%)
NFLX   361.76 (-2.25%)
BAC   20.03 (-2.63%)
GILD   78.21 (+1.60%)
DIS   93.88 (-3.19%)
PRI   80.69 (-2.50%)
Log in

NASDAQ:INMBINmune Bio Stock Price, Forecast & News

$3.10
-0.17 (-5.20 %)
(As of 04/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$3.10
Now: $3.10
$3.41
50-Day Range
$2.21
MA: $3.89
$5.29
52-Week Range
$2.20
Now: $3.10
$11.50
Volume900 shs
Average Volume31,686 shs
Market Capitalization$33.32 million
P/E RatioN/A
Dividend YieldN/A
Beta1.54
INmune Bio Inc., a clinical-stage immunotherapy company, focuses on engineering and harnessing the innate immune system to treat the patient's cancer. The company intends to develop and commercialize product candidates to treat diseases comprising hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma; and INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation, including elevated levels of myeloid derived suppressor cells in their blood. The company was founded in 2015 and is based in La Jolla, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.79 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:INMB
CUSIPN/A
CIKN/A
Phone858-964-3720

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.19 per share

Profitability

Net Income$-7,680,000.00

Miscellaneous

Employees3
Market Cap$33.32 million
Next Earnings Date6/10/2020 (Estimated)
OptionableNot Optionable

Receive INMB News and Ratings via Email

Sign-up to receive the latest news and ratings for INMB and its competitors with MarketBeat's FREE daily newsletter.


INmune Bio (NASDAQ:INMB) Frequently Asked Questions

How has INmune Bio's stock been impacted by COVID-19 (Coronavirus)?

INmune Bio's stock was trading at $4.80 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, INMB shares have decreased by 35.4% and is now trading at $3.10. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of INmune Bio?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for INmune Bio in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for INmune Bio.

When is INmune Bio's next earnings date?

INmune Bio is scheduled to release its next quarterly earnings announcement on Wednesday, June 10th 2020. View our earnings forecast for INmune Bio.

How were INmune Bio's earnings last quarter?

INmune Bio Inc (NASDAQ:INMB) issued its earnings results on Wednesday, March, 11th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.03. View INmune Bio's earnings history.

What price target have analysts set for INMB?

3 Wall Street analysts have issued twelve-month price objectives for INmune Bio's shares. Their forecasts range from $8.00 to $13.00. On average, they expect INmune Bio's share price to reach $11.33 in the next year. This suggests a possible upside of 265.6% from the stock's current price. View analysts' price targets for INmune Bio.

What are Wall Street analysts saying about INmune Bio stock?

Here are some recent quotes from research analysts about INmune Bio stock:
  • 1. HC Wainwright analysts commented, "We maintain our Buy rating of INMB and our 12-month price target of $11.50 per share. We derive our price target based on a risk-adjusted net present value (rNPV) analysis of projected future revenues from 2030, assuming a 13% discount rate and a 0.5% terminal growth rate. We derive an rNPV of $345M for the products and add in cash and cash equivalents of $9.4M to arrive at a 12-month price target of $11.43 per diluted share, which we round to $11.50." (9/12/2019)
  • 2. Maxim Group analysts commented, "INmune Bio reported 2Q19 with operating expenses of ~$2M, partially offset by a $1.5M non-cash charge (waiver of common stock issuable); net loss was ($0.4M). The company ended the period with $9.4M in cash on the balance sheet. In addition, recall that as a result of the $1M grant from the Alzheimer’s foundation and also conducting trials abroad which comes with significant R&D reimbursement, the runway is further extended." (8/14/2019)

Has INmune Bio been receiving favorable news coverage?

Media stories about INMB stock have trended very negative this week, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. INmune Bio earned a news impact score of -3.3 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutINmune Bio.

Are investors shorting INmune Bio?

INmune Bio saw a drop in short interest in the month of March. As of March 13th, there was short interest totaling 3,100 shares, a drop of 74.6% from the February 27th total of 12,200 shares. Based on an average trading volume of 98,500 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.1% of the shares of the stock are sold short. View INmune Bio's Current Options Chain.

Who are some of INmune Bio's key competitors?

What other stocks do shareholders of INmune Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other INmune Bio investors own include Canadian Solar (CSIQ), Spectrum Pharmaceuticals (SPPI), Axon Enterprise (AAXN), Ambarella (AMBA), AbbVie (ABBV), General Motors (GM), IBM (IBM), Main Street Capital (MAIN), AT&T (T) and Verizon Communications (VZ).

Who are INmune Bio's key executives?

INmune Bio's management team includes the following people:
  • Dr. Raymond Joseph Tesi, Co-Founder, Pres, CEO & Director (Age 63)
  • Mr. David J. Moss M.B.A., CFO, Treasurer & Sec. (Age 49)
  • Dr. Mark William Lowdell BSc, MSc, Ph.D., FRCPath, MICR, Chief Scientific Officer (Age 56)

What is INmune Bio's stock symbol?

INmune Bio trades on the NASDAQ under the ticker symbol "INMB."

How do I buy shares of INmune Bio?

Shares of INMB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is INmune Bio's stock price today?

One share of INMB stock can currently be purchased for approximately $3.10.

How big of a company is INmune Bio?

INmune Bio has a market capitalization of $33.32 million. The company earns $-7,680,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis. INmune Bio employs 3 workers across the globe. View additional information about INmune Bio.

What is INmune Bio's official website?

The official website for INmune Bio is http://www.inmunebio.com/.

How can I contact INmune Bio?

INmune Bio's mailing address is 1200 PROSPECT STREET SUITE 525, LA JOLLA CA, 92037. The company can be reached via phone at 858-964-3720 or via email at [email protected]

This page was last updated on 4/3/2020 by MarketBeat.com Staff

Featured Article: Inverted Yield Curve

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel